

Edgar Filing: Raptor Pharmaceutical Corp - Form 8-K

Item 2.02 Results of Operations and Financial Condition.

On March 14, 2013, Raptor Pharmaceutical Corp., a Delaware corporation (the "Company"), issued a press release reporting its financial results for the Company's four month transition period from September 1, 2012 to December 31, 2012. A copy of the press release is being furnished as Exhibit 99.1 and is incorporated herein by reference.

The information included in this Item 2.02 of this Current Report on Form 8-K, including the information incorporated by reference in the exhibit hereto, shall not be deemed "filed" for purposes of, nor shall it be deemed incorporated by reference in, any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

		Furnished			
Exhibit		Here	Incorporated by Reference		
No.	Exhibit Description	with	Form File No.	Exhibit Filing Date	Filed By
99.1	Press release issued by the Company dated as of March 14, 2013	X			

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RAPTOR
PHARMACEUTICAL CORP.

Date: March 14, 2013 By: /s/ Kim R. Tsuchimoto
Name: Kim R. Tsuchimoto
Title: Vice President, Finance

Edgar Filing: Raptor Pharmaceutical Corp - Form 8-K

Exhibit Index

Exhibit	Exhibit Description	Furnished	Incorporated by Reference	Form File No. Exhibit Filing Date	Filed By
99.1	Press release issued by the Company dated as of March 14, 2013	X			